Huayi Li
-
- Stock Market Forecasting Methods 3
-
- PARP inhibition in cancer therapy 8
- CAR-T cell therapy research 4
- Finance top 10%
- Artificial Intelligence top 10%
- Advanced Text Analysis Techniques 2
-
- Immune Cell Function and Interaction 3
-
- Ovarian cancer diagnosis and treatment 4
-
- CRISPR and Genetic Engineering 4
-
- Virus-based gene therapy research 2
- Journals
- Journal of Clinical Oncology (1 paper)SHILAP Revista de lepidopterología (2 papers)Oncogene (1 paper)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Huayi Li
24 papers receiving 485 citations
Peers
Comparison fields: 5 of 96
- Management Science and Operations Research 120
- Oncology 119
- Finance 41
- Artificial Intelligence 113
- Immunology 71
Countries citing papers authored by Huayi Li
This map shows the geographic impact of Huayi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huayi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huayi Li more than expected).
Fields of papers citing papers by Huayi Li
This network shows the impact of papers produced by Huayi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huayi Li. The network helps show where Huayi Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Huayi Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 10 | |
| 5 | 2023 | 10 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 9 | |
| 8 | 2023 | 22 | |
| 9 | 2023 | 4 | |
| 10 | 2023 | 19 | |
| 11 | 2022 | 2 | |
| 12 | 2022 | 12 | |
| 13 | 2022 | 70 | |
| 14 | 2021 | 18 | |
| 15 | 2021 | 19 | |
| 16 | 2021 | 9 | |
| 17 | 2016 | 15 | |
| 18 | 2014 | 46 | |
| 19 | 2013 | 18 | |
| 20 | 2013 | 145 |
About Huayi Li
Huayi Li is a scholar working on Health Informatics, Oncology and Reproductive Medicine, having authored 26 papers that have together received 507 indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (8 papers), CAR-T cell therapy research (4 papers), Ovarian cancer diagnosis and treatment (4 papers), CRISPR and Genetic Engineering (4 papers), Stock Market Forecasting Methods (3 papers), Immune Cell Function and Interaction (3 papers), Virus-based gene therapy research (2 papers) and Advanced Text Analysis Techniques (2 papers). The work is most often cited by research in Management Science and Operations Research (120 citations), Oncology (119 citations) and Finance (41 citations). Huayi Li has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Qing Li, Jianfeng Si, Arjun Mukherjee, Bing Liu, Qinglei Gao, Xiaotie Deng, Sinno Jialin Pan, Bing Liu, Sen Xu and Dongchen Zhou. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.